News
-
AstraZeneca And Amgen Announce Collaboration To Jointly Develop And Commercialise Clinical-Stage Inflammation Portfolio
4/4/2012
AstraZeneca and Amgen recently announced an agreement to jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio: AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827).
-
Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis
3/29/2012
New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's (NYSE: LLY) ixekizumab (pronounced ix" e kiz' ue mab, previously known as LY2439821), an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.
-
iBio Announces Successful Completion Of H1N1 Influenza Vaccine Phase 1 Clinical Trial
3/22/2012
iBio, Inc. (NYSE AMEX: IBIO) today announced completion of the first human trial of iBioLaunch-produced H1N1 influenza vaccine (HAC1) that began September 13, 2010. This Phase 1, single-blind, placebo-controlled, dose-escalation study was conducted to assess the safety and reactogenicity and immunogenicity of HAC1 produced by iBio's research collaborator, the Fraunhofer USA Center for Molecular Biotechnology.
-
Shire To Initiate Two Phase 4 Clinical Trials To Compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) To Concerta (methylphenidate HCl) Extended-Release Tablets, (CII)
3/8/2012
As part of its continued commitment to ADHD research, Shire plc., the global specialty biopharmaceutical company, recently announced it is initiating two Phase 4 clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta (methylphenidate HCl) Extended-Release Tablets, (CII).
-
FDA Approves First Quadrivalent Vaccine To Prevent Seasonal Influenza
3/1/2012
FluMist Quadrivalent, a vaccine to prevent seasonal influenza in people ages 2 years through 49 years, has been approved today by the U.S. Food and Drug Administration.
-
Enlivex Completes Patient Enrollment In Its Phase I/II Clinical Trial
1/24/2012
Hadasit Bio-Holdings (TASE: HDST, OTC: HADSY) a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.
-
Sumagen Initiates Clinical Testing Of Omnia Biologics Manufactured HIV Vaccine
1/12/2012
Biologics drug development and manufacturing services provider Omnia Biologics, Inc. (Omnia) (Rockville, MD) today announced that its customer Sumagen, Co., Ltd., (Seoul, S. Korea and London, ON) will begin clinical trials of their revolutionary HIV vaccine design.
-
CROS NT Announces Further Expansion Into The UK Market
1/11/2012
CROS NT is starting the new year by announcing its expansion into the United Kingdom.
-
Sangamo BioSciences Announces Initiation Of Two New Phase 2 HIV Clinical Trials
1/10/2012
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS.
-
Achillion Reports Clinical Data On Portfolio Of Protease Inhibitors
1/10/2012
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported new clinical trial results on its portfolio of protease inhibitors including: Phase 2 interim 12-week treatment results with ACH-1625 for the treatment of genotype 1 treatment-naive hepatitis C virus (HCV), exploratory data on ACH-1625 for the treatment of HCV genotype 3, and initial proof-of-concept data for ACH-2684.
This website uses cookies to ensure you get the best experience on our website. Learn more